CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway (Apr, 10.1007/s13311-021-01038-1, 2021)NEUROTHERAPEUTICSIF6.92021-07-011OAAI
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling PathwayNEUROTHERAPEUTICSIF6.92021-07-019OAAI
DNA damage response in responder lymphocytes reduces vaccine efficacy following alkylating chemotherapy.CANCER RESEARCHIF16.62014-04-020PRE
Direct in vitro generation of antigen specific, memory phenotype, Cd8+T cells using a cocktail of small molecules and gamma-chain cytokinesCYTOKINEIF3.72013-09-010PREAI
Profound Impairment of Adaptive Immune Responses by Alkylating ChemotherapyJOURNAL OF IMMUNOLOGYIF3.42013-06-1571OAAI
Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted AgentsMOLECULAR CANCER THERAPEUTICSIF5.52012-10-0988OAAI
Identification and characterization of a novel scFv recognizing human and mouse CD133DRUG DELIVERY AND TRANSLATIONAL RESEARCHIF5.52012-09-0122OA
Immunotoxin targeting CD133+ breast carcinoma cellsDRUG DELIVERY AND TRANSLATIONAL RESEARCHIF5.52012-05-0236PRE
Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic OxygenCLINICAL CANCER RESEARCHIF10.22010-09-2937OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向